Merus (NASDAQ:MRUS) Receives $85.64 Consensus PT from Analysts

Shares of Merus (NASDAQ:MRUS) have been given a consensus rating of “Buy” by the fourteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Twelve analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $85.64.

Several equities research analysts have recently weighed in on MRUS shares. The Goldman Sachs Group assumed coverage on Merus in a research report on Thursday, November 21st. They issued a “buy” rating and a $73.00 price objective for the company. UBS Group started coverage on shares of Merus in a report on Thursday, October 24th. They issued a “buy” rating and a $72.00 price target for the company. HC Wainwright restated a “buy” rating and set a $85.00 price objective on shares of Merus in a report on Monday, December 2nd. Citigroup upped their price objective on shares of Merus from $89.00 to $97.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Finally, Guggenheim reissued a “buy” rating and set a $109.00 target price (down from $111.00) on shares of Merus in a research report on Tuesday, December 3rd.

Institutional Trading of Merus

Institutional investors have recently bought and sold shares of the stock. nVerses Capital LLC grew its stake in Merus by 750.0% during the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after buying an additional 1,500 shares during the last quarter. US Bancorp DE acquired a new position in shares of Merus in the 3rd quarter worth approximately $103,000. Mirae Asset Global Investments Co. Ltd. grew its position in Merus by 24.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 489 shares during the last quarter. MML Investors Services LLC acquired a new stake in Merus during the 3rd quarter valued at $206,000. Finally, Farallon Capital Management LLC acquired a new stake in Merus during the 2nd quarter valued at $237,000. Institutional investors and hedge funds own 96.14% of the company’s stock.

Merus Price Performance

Merus stock opened at $41.89 on Friday. Merus has a fifty-two week low of $27.11 and a fifty-two week high of $61.61. The firm has a fifty day moving average price of $46.84 and a two-hundred day moving average price of $50.59. The firm has a market cap of $2.87 billion, a price-to-earnings ratio of -10.61 and a beta of 1.07.

Merus (NASDAQ:MRUS) last posted its quarterly earnings data on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.05). The business had revenue of $11.77 million for the quarter, compared to analyst estimates of $9.11 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. As a group, sell-side analysts expect that Merus will post -3.89 earnings per share for the current year.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.